N/A N=50 TUI 3D in Diagnosis of Placenta Accreta: Comparison With Gray-scale and Color Doppler Techniques
Placenta Accreta
Primary: Loss of the Retro Placental Sonolucent Zone by 2D Grayscale Ultrasonography — 12; 19 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 Histerectomy Vs Partial Myometrial Resection for Placenta Accreta Spectrum
Placenta Accreta
Primary: Feasibility: Proportion of Eligible Patients Who Agree to Participate in the Study. — 60 Participants
Phase 4 N=14 Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study
Placenta Accreta · Postpartum Hemorrhage · Cesarean Section
Primary: Estimated Blood Loss (EBL) — 3116; 9420 cc
N/A N=60 Predicting Placental Pathologies by Ultrasound Imaging
Intrauterine Growth Restriction · Villitis · IUGR
Primary: Number of Participants With Uterine Artery Indices Completed — 13; 3 Participants
N/A N=251 Optimisation of the Management of Placental Delivery in Second Trimester Pregnancy Interruption
Placenta, Retained · Postpartum Hemorrhage
Primary: Placental Retention Rate — 26; 8; 24 participants — p=0.05
N/A N=120 Influence of Acupuncture in the Placental Expulsion Time
Placental Expulsion Time
Primary: The Principal Outcome of the Study is the Placental Expulsion Time. — 15.21; 5.23 minutes — p=<0.001
N/A N=112 Immediate Postplacental Insertion of IUDs at Time of Cesarean Delivery: A Randomized Clinical Trial
Intrauterine Devices · Cesarean Section
Primary: IUD Use — 32; 40 participants
Early Phase 1 N=3 Placental Lesions in Fetal Growth Restrictions
Fetal Growth Retardation
Primary: Number of Participants for Which Intervillous Placental Blood is Detected — 3 Participants
Phase 3 N=120 Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery
Uterine Atony · Uterine Atony With Hemorrhage · Postpartum Hemorrhage
Primary: Quantitative Blood Loss — 840; 1051 milliliters — p=<0.05
N/A N=68 Optimal Management of Vasa Previa Study - A Retrospective Study
Vasa Previa
Primary: Diagnostic Profile of Techniques Utilized to Screen for and Diagnose Vasa Previa During Pregnancy. — 47; 13; 4; 2 Participants
Phase 2 N=100 The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery
Hemorrhage
Primary: The Amount of Hemorrhage During Cesarean Delivery and Within 2 Hours Afterward — 260; 380 ml
Phase 4 N=7 Intrauterine Contraceptive Device (IUD) Placement at Time of C-Section
Contraception
Primary: Successful Retention of IUD — 7 participants
Phase 4 N=90 Copper Intrauterine Device (IUD) Insertion at Cesarean Delivery
Intrauterine Device Expulsion
Primary: Number of Participants With Expulsion of IUD — 54; 0 Participants
N/A N=4 Temporary Aortic Occlusion With the Abdominal Tourniquet for Refractory Postpartum Haemorrhage: A Proof-of-Concept Study in a War-Affected Region
Postpartum Haemorrhage (PPH)
Primary: Time to Bleeding Control After AAJT-S Device Application — 2 Minutes
N/A N=5 Randomized Clinical Trial: Expectant Management vs Laser Treatment of Monochorionic Twins With Severe Selective Intrauterine Growth Retardation and Absent or Reverse Diastolic Flow in the Umbilical Artery
Intrauterine Growth Retardation
Primary: Survival — 100; 100 percentage of AGA babies who survived
Phase 3 N=11,000 Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean
Obstetrical Complications · Hemorrhage · Labor and Delivery
Primary: Number of Participants With Maternal Death or Transfusion of Packed Red Blood Cells — 201; 233 Participants — p=0.19
Phase 2 N=40 Calcium Chloride for Prevention of Uterine Atony During Cesarean
Uterine Atony · Uterine Atony With Hemorrhage · Cesarean Section Complications
Primary: Uterine Atony — 4; 10 Participants
Phase 2 N=208 Role of ASpirin in Placental and Maternal Endothelial Cell Regulation IN Pre-eclampsia
Pre-Eclampsia
Primary: Change in Pulsatility Index (PI) — -0.56; -0.53; -0.43; -0.88 ratio
N/A N=29 Mirena Intrauterine System Timing of Insertion: A Randomized Controlled Trial
Postpartum Period
Primary: Mirena in Place — 10; 3 participants
N/A N=24 Coagulation Factor Changes Associated With Postpartum Hysterectomies
Obstetric Labor Complications · Hemorrhage · Complications; Cesarean Section
Primary: Fibrinogen Level at 2 Hours After Delivery — 186; 418 mg/dL — p=<0.05
N/A N=480 Maternal Lifestyle and Neonatal Hypoglycemia
Hyperinsulinemia · Miscarriages · Pregnancy
Primary: Neonatal Hypoglycemia — 3; 15 neonates
N/A N=102 Postplacental or Delayed Insertion of the Levonorgestrel-releasing Intrauterine Device (IUD) After Vaginal Delivery
Contraception
Primary: IUD Usage Rate at 6 Months — 43; 39 participants
N/A N=10 Feasibility Clinical Investigation Using the InPress Device for the Treatment of Postpartum Hemorrhage
Post Partum Hemorrhage
Primary: Number of Related SAE — 0 SAEs
Phase 4 N=18 Trial of IV NTG for CD After Second Stage Arrest for the Prevention of Uterine Extension
Prolonged Second Stage of Labor
Primary: Number of Participants With Uterine Extension of Hysterotomy — 3; 4 Participants
N/A N=93 Reproductive Outcome Affected by Two Adjunctive Treatments in Patients With Severe Intrauterine Adhesions
Asherman's Syndrome
Primary: Number of Participants With Pregnancy in Loop-shaped Intrauterine Device Group and Intrauterine Balloon Group — 12; 22 participants — p=0.009
Phase 3 N=102 A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia
Alloimmune Thrombocytopenia · Fetal Alloimmune Thrombocytopenia
Primary: Number of Newborns With a Birth Platelet Count > 50,000/uL — 48; 47 number of newborns with >50,000 pets
Phase 4 N=123 Buccal Misoprostol During Cesarean Section for Preventing Postpartum Hemorrhage
Postpartum Hemorrhage
Primary: Need for Additional Uterotonic Medications — 10; 40 percentage of participants — p=<0.01
N/A N=106 Accuracy of Blood Loss Estimation After Vaginal Delivery
Postpartum Hemorrhage
Primary: Difference in Actual Blood Volume and Estimated Blood Volume in Milliliters. — -20.8; -41.7; -53.5; -96.0 milliliters — p=<0.05
N/A N=30 Magnesium Sulfate vs Placebo for Placental Abruption
Abruptio Placentae
Primary: Undelivered With Resolution of Vaginal Bleeding and Contractions in First 48 Hours — 12; 10 participants — p=0.68
N/A N=242 Validating a New Method to Assess Estimated Blood Loss in the Obstetric Population
Pregnancy Complications
Primary: Clinical Estimated Blood Loss (EBL) Between Cases and Controls Using Clinical Estimate Versus Device Assessment — 800; 800 milliLiters